Several new 4-(3,3-dimethyltriazeno)-5-benzamidopyrazole derivatives were prepared by reacting 4-diazo-5-benzamidopyrazole derivatives with dimethylamine. The compounds were tested at 10 μM for their vitro antileukemic activity against K562 (Human chronic myelogenous leukemia) and Raji (human Burkitt limphoma ) cell lines. Dacarbazine and methotrexate were used for comparative purpose. The 3-methyl-4-(3,3-dimethyltriazeno)-5-(substituted benzamido)pyrazoles, bearing the pyrazole nucleus free at 1 position, resulted more active than the 1-(substituted phenyl)-3-methyl-4-(3,3-dimethyltriazeno)-5-benzamidopyrazoles. Dacarbazine at 10 μM showed no activity in the above tests. The observed difference among Dacarbazine and the active 4-triazenopyrazoles migth be explained admiting that these last compounds, differently by Dacarbazine, did not follow a mechanism of action based on the cytochrome P-450 induced demethylation. The most active compound 2d showed growth inhibition values of 97.8 and 99.4% against K562 and Raji cell lines respectively. Methotrexate inhibition values at 0.2 μM against the above cell lines were 86.7 and 75.1% respectively.

DAIDONE G, MAGGIO B, RAFFA D, PLESCIA S, SCHILLACI D, RAIMONDI MV (2004). SYNTHESIS AND IN VITRO ANTILEUKEMIC ACTIVITY OF NEW 4-TRIAZENOPYRAZOLE DERIVATIVES. IL FARMACO, 59(5), 413-417 [10.1016/j.farmac.2004.01.016].

SYNTHESIS AND IN VITRO ANTILEUKEMIC ACTIVITY OF NEW 4-TRIAZENOPYRAZOLE DERIVATIVES

DAIDONE, Giuseppe;MAGGIO, Benedetta;RAFFA, Demetrio;PLESCIA, Salvatore;SCHILLACI, Domenico;RAIMONDI, Maria Valeria
2004-01-01

Abstract

Several new 4-(3,3-dimethyltriazeno)-5-benzamidopyrazole derivatives were prepared by reacting 4-diazo-5-benzamidopyrazole derivatives with dimethylamine. The compounds were tested at 10 μM for their vitro antileukemic activity against K562 (Human chronic myelogenous leukemia) and Raji (human Burkitt limphoma ) cell lines. Dacarbazine and methotrexate were used for comparative purpose. The 3-methyl-4-(3,3-dimethyltriazeno)-5-(substituted benzamido)pyrazoles, bearing the pyrazole nucleus free at 1 position, resulted more active than the 1-(substituted phenyl)-3-methyl-4-(3,3-dimethyltriazeno)-5-benzamidopyrazoles. Dacarbazine at 10 μM showed no activity in the above tests. The observed difference among Dacarbazine and the active 4-triazenopyrazoles migth be explained admiting that these last compounds, differently by Dacarbazine, did not follow a mechanism of action based on the cytochrome P-450 induced demethylation. The most active compound 2d showed growth inhibition values of 97.8 and 99.4% against K562 and Raji cell lines respectively. Methotrexate inhibition values at 0.2 μM against the above cell lines were 86.7 and 75.1% respectively.
2004
Settore CHIM/08 - Chimica Farmaceutica
Settore BIO/19 - Microbiologia Generale
DAIDONE G, MAGGIO B, RAFFA D, PLESCIA S, SCHILLACI D, RAIMONDI MV (2004). SYNTHESIS AND IN VITRO ANTILEUKEMIC ACTIVITY OF NEW 4-TRIAZENOPYRAZOLE DERIVATIVES. IL FARMACO, 59(5), 413-417 [10.1016/j.farmac.2004.01.016].
File in questo prodotto:
File Dimensione Formato  
1s.pdf

Solo gestori archvio

Descrizione: Articolo
Dimensione 173.19 kB
Formato Adobe PDF
173.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/24046
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 54
  • ???jsp.display-item.citation.isi??? ND
social impact